AI Article Synopsis
- - Repotrectinib, a new ROS1 tyrosine kinase inhibitor, was licensed in November 2023 and is effective against a common mutation that makes previous ROS1 TKIs less effective.
- - A patient with advanced NSCLC and specific mutations initially responded well to repotrectinib but later developed resistance due to the emergence of a new mutation.
- - The patient's disease then responded to cabozantinib, another ROS1 TKI from a different class that showed preclinical efficacy against the new mutation.
Article Abstract
Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against , the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretreated, with advanced and mutated rearranged NSCLC, who initially responded to repotrectinib but later developed further on-target resistance with the emergence of an mutation. The disease then responded to cabozantinib, a separate class of ROS1 TKI with preclinical activity against .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293496 | PMC |
| http://dx.doi.org/10.1016/j.jtocrr.2024.100673 | DOI Listing |
Publication Analysis
Top Keywords
l2086f mutant
4
mutant ros1-rearranged
4
ros1-rearranged nsclc
4
nsclc resistant
4
resistant repotrectinib
4
repotrectinib responds
4
responds cabozantinib
4
cabozantinib case
4
case report
4
report repotrectinib
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!